1. Introduction {#sec1}
===============

Ion channels are transmembrane proteins that allow the passage of ions according to the direction of their electrochemical gradients across cell membranes. They are pore-forming membrane proteins whose normal function is critical for several physiological processes in cells. In excitable cells, such as cardiac cells, the activity of these proteins maintains the resting membrane potential and generates action potentials that are essential for excitation-contraction coupling process.

Ion channel dysfunction is the principal pathophysiological mechanism underlying various inherited forms of arrhythmic disorders, also called channelopathies \[[@B1]\]. In cardiac cells, mutations in more than 30 genes encoding ion channels have been associated with an increasingly wide range of inherited cardiac arrhythmias \[[@B1]\]. Examples of genetic cardiac disorders include congenital ectopic Purkinje-related premature contractions (MEPPC) and exercise induced polymorphic ventricular tachycardia (EPVT) which have been linked to the presence of the Na~v1.5~-p.R222Q and Na~v1.5~-p.I141V mutations \[[@B2]--[@B4]\].

The ECG of the Na~v1.5~-p.R222Q carriers displayed atrial fibrillation, narrow junctional, and rare sinus beats competing with numerous premature ventricular contractions. The observed arrhythmia disappears under exercise \[[@B2], [@B3]\]. For Na~v1.5~-p.I141V carriers, the ECG is characterized by an increased sinus rate, atrial tachyarrhythmias, and an increased number of ventricular complexes during exercise \[[@B4]\]. On the molecular level, these mutations affect the biophysical properties of Na~v1.5~ by shifting its voltage dependence of steady state of activation towards more negative potentials and accelerating its activation and inactivation kinetics \[[@B2]--[@B6]\].

Ion channels become one of the most important molecular targets for several classes of drugs including antiarrhythmics and local anesthetic molecules \[[@B7]\]. In this sense, green tea flavonoids could offer a natural promising alternative. Indeed, Epigallocatechin-3-Gallate (E3G), as a major flavanol of green tea, has shown significant effects on the electrocardiographic wave forms in guinea pig. This compound has been demonstrated to exhibit inhibitory action on several cardiac ion channels \[[@B8]\].

Tea is manufactured from the dried leaves of*Camellia sinensis*in three basic forms of nonoxidized (green), semioxidized (oolong), and oxidized (black). Green tea is one of the most widely consumed beverages in North Africa and exhibits high content in polyphenolic flavanols known as catechins which may constitute up to 36% of the dry leaf weight \[[@B9], [@B10]\]. Catechins represent 80% to 90% of green tea total flavonoids, where epigallocatechin gallate appears to be the major predominant catechin (48--55%) followed by epigallocatechin (9--12%), epicatechin gallate (9--12%), epicatechin (5--7%), and a small proportion of catechin (0.3--0.6%) \[[@B11]\].

Most flavonoids affect vascular system insofar to normalize blood pressure by either inhibiting calcium channels or activating potassium channels or both. But contrary to the clear-cut pathophysiological benefit of flavonoids on vascular system, the impact of these compounds on cardiac channelopathies is yet somewhat unclear \[[@B12]\]. Previous investigation using patch clamp technique showed that flavonoids act as multichannel inhibitors, thereby triggering generally unexpected pharmacological effects. Therefore, the reported effects on cardiac ion channels of most flavonoids remain largely unknown whether they are anti- or proarrhythmic \[[@B12], [@B13]\]. In this sense, voltage gated sodium channel (VGSC) inhibition by polyphenols is well documented as cardioprotective and antiarrhythmic pathways. Catechins, like other polyphenols, share the common structural feature of one or more phenolic rings with several antiarrhythmic VGSC inhibitors such as lidocaine and mexiletine. These polyphenolic compounds may also inhibit peak and/or late *I* ~Na~, leading to beneficial impact on the parameters associated with arrhythmias.

In this context, the aim of this study was to evaluate the benefits-risks balance of E3G effect on the setting of cardiac channelopathies.

2. Materials and Methods {#sec2}
========================

2.1. Models {#sec2.1}
-----------

The action potentials were simulated using the updated mathematical model of the human atrial action potential of Maleckar-Greenstein-Trayanova-Giles (MGTG) \[[@B14]\], Stewart--Aslanidi--Noble--Noble--Boyett--Zhang (SANNBZ) Purkinje cell model \[[@B15]\], and Tusscher--Noble--Noble--Panfilov (TNNP) human ventricular cell models \[[@B16]\].

2.2. Formulation of Fast Sodium Current {#sec2.2}
---------------------------------------

In TNNP and SANNBZ models, the sodium current *I* ~Na~ is represented according to a Hodgkin--Huxley formalism: *I* ~Na~ = *g* ~Na~ *m* ^3^ *hj*(*V* ~m~ − *E* ~Na~), where *g* ~Na~ is the maximal conductance of *I* ~Na~. *m* ^3^, *h*, and *j* are the activation gate, fast inactivation gate, and slow inactivation gate, respectively. *V* ~m~ represents the membrane potential, and *E* ~Na~ is the Nernst potential of sodium.

For the MGTG atrial model, the sodium current *I* ~Na~ is represented according to the following equation:$$\begin{matrix}
I_{\text{Na}} \\
{\mspace{20mu} = P_{\text{Na}}m^{3}\left( { 0.9h_{1} + 0.1h_{2}} \right)\left\lbrack {\text{Na}^{+}} \right\rbrack_{c}V\frac{F^{2}}{\text{RT}}\frac{e^{{({V - E_{\text{Na}}})}{F/\text{RT}}} - 1}{e^{{VF}/\text{RT}} - 1},} \\
\end{matrix}$$where *P* ~Na~ represents the permeability to the sodium and *m* ^3^,*h* ~1~, and *h* ~2~ are the activation gate, fast inactivation gate, and slow inactivation gate, respectively. *V* represents the membrane potential, and *E* ~Na~ is the Nernst potential of sodium.

2.3. Computer Modeling of Na~v1.5~-p.R222Q and Na~v1.5~-p.I141V Mutants {#sec2.3}
-----------------------------------------------------------------------

The same strategy was used for all models of the atrial, human Purkinje cells, and left-ventricular myocytes \[[@B15]--[@B18]\]. As reported by Mann et al., 2012, and Swan et al., 2014, \[[@B3], [@B4]\], the equations corresponding to the *I* ~Na~ current were modified to reproduce the relative variation of biophysical properties of the sodium current due to the Na~v1.5~-p.R222Q and Na~v1.5~-p.I141V mutations.

The effects of the Na~v1.5~-p.R222Q and Na~v1.5~-p.I141V mutations were simulated as previously described by Mann et al., 2012, and Swan et al., 2014, for the ventricular and Purkinje models \[[@B3], [@B4]\]. *m* ~*∞*~, *h* ~*∞*~, *α* ~*m*~, *β* ~*m*~, and *β* ~*h*~ were modified to reproduce the shift in the voltage dependencies of steady state of activation and inactivation and their kinetics. For the MGTG atrial model, *m* ~*∞*~, *m* factor, *h* ~*∞*~, and *h* factor were modified to reproduce the shift of the activation and inactivation curves as well as the changes observed in the sodium current kinetics. In all conditions, the heterozygous states were reproduced by the summation of half the WT current and half the mutant current.

2.4. Computer Modeling of Epigallocatechin-3-Gallate Effect on Ion Channels {#sec2.4}
---------------------------------------------------------------------------

For all models and conditions (WT and mutants), the effects of E3G on ion channels were reproduced based on the experimental work of Kang et al. \[[@B8]\].

[Table 1](#tab1){ref-type="table"} summarizes the modifications of the cardiac ion currents that were introduced in all models to match the experimental Data.

2.5. Conduction Velocity {#sec2.5}
------------------------

Conduction velocity was investigated in fibers of MGTG, TNNP, and SANNBZ cell models (pacing rates: 1 Hz for the atrial and ventricular models and 2.5 Hz for the Purkinje model). [Table 3](#tab3){ref-type="table"} summarizes the parameters used for the calculation of conduction velocity.

All simulations were performed by Myokit v.1.20.5 \[[@B19]\].

3. Results {#sec3}
==========

3.1. Simulated Effect of E3G on the Electrical Activity of Cardiac Cells {#sec3.1}
------------------------------------------------------------------------

To investigate the functional consequences of 30 *μ*M E3G on the electrical activity of atrial, Purkinje, and ventricular cells, we used MGTG, SANNBZ, and human epicardial, midmyocardial, and endocardial ventricular TNNP cell models. Using these models, the observed changes in cardiac ion channels function such as voltage dependencies and current amplitudes were implemented (see [Section 2](#sec2){ref-type="sec"}, Figures [1](#fig1){ref-type="fig"} [](#fig2){ref-type="fig"}--[3](#fig3){ref-type="fig"}).

In the *I* ~Na~ formulations of MGTG, SANNBZ, and TNNP cell models, the effects of E3G on the sodium channel function were simulated by shifting the voltage dependence of the steady state equilibrium *h* ~*∞*~ of *h* gate by −6 mV (Figures [1(a)](#fig1){ref-type="fig"}, [2(a)](#fig2){ref-type="fig"}, and [3(a)](#fig3){ref-type="fig"}). The *m* and *j* gates were left unchanged.

The introduction of a negative shift in the inactivation curve, related to the presence of E3G, allowed us to reproduce the inhibitory effect of this compound on the sodium current amplitude for the ventricular and Purkinje cell models (Figures [2(b)](#fig2){ref-type="fig"}, [2(c)](#fig2){ref-type="fig"}, [3(b)](#fig3){ref-type="fig"}, and [3(c)](#fig3){ref-type="fig"}). Indeed, as reported by Kang et al. \[[@B8]\], the inhibitory effect of E3G is higher at depolarized resting potentials. However, for the atrial cell model, we observed that 30 *μ*M E3G decreases the sodium current amplitude only when the resting potential is maintained at −70 mV (Figures [1(b)](#fig1){ref-type="fig"} and [1(c)](#fig1){ref-type="fig"}). There is no E3G effect when the resting potential is maintained at −90 mV. This is due to the biophysical properties of inactivation at basal condition. In fact, as shown in [Figure 1(a)](#fig1){ref-type="fig"}, there is no difference in the sodium channel availability with or without E3G at −90 mV. Thus, an equal number of sodium channels were available in both conditions when the membrane was maintained at this potential.

Moreover, by using the same voltage protocols described by Kang et al., the inhibitory effect of 30 *μ*M E3G on *I* ~CaL~ and *I* ~Ks~ currents was reproduced via decreasing the amplitude of these currents to 80% and 50% of WT amplitude, respectively (Figures [1(d)](#fig1){ref-type="fig"}, [1(e)](#fig1){ref-type="fig"}, [2(d)](#fig2){ref-type="fig"}, [2(e)](#fig2){ref-type="fig"}, [3(d)](#fig3){ref-type="fig"}, and [3(e)](#fig3){ref-type="fig"}). All used formulations are summarized in Tables [1](#tab1){ref-type="table"} and [2](#tab2){ref-type="table"} (see [Section 2](#sec2){ref-type="sec"}). Simulations were run for 60 s with a cycle length of 1 Hz to stabilize the model. Then, supplementary run was started for another 5 s and then the last AP of each supplementary run was analyzed.

The combined effects of 30 *μ*M E3G on cardiac ion channels slightly decreased the AP amplitudes and maximum upstroke velocities of atrial, Purkinje, and ventricular cells (Figures [1(f)](#fig1){ref-type="fig"}, [2(f)](#fig2){ref-type="fig"}, and [3(f)](#fig3){ref-type="fig"}). In addition, the plateau phase of atrial AP was reduced ([Figure 1(f)](#fig1){ref-type="fig"}). However, E3G increased AP duration in Purkinje cell model ([Figure 2(f)](#fig2){ref-type="fig"}).

For midmyocardial cells, E3G shortened the AP duration ([Figure 3(f)](#fig3){ref-type="fig"}). On the other hand, the superimposition of the epi-, midmyo-, and endocardial APs predicted a small decrease of the repolarization dispersion across the ventricular wall ([Figure 4](#fig4){ref-type="fig"}).

3.2. The p.R222Q and p.I141V Effects on Cardiac Excitability {#sec3.2}
------------------------------------------------------------

According to the experimental work of Kang et al. \[[@B8]\], the E3G antiarrhythmic effect, in the sitting of MEPPC and EPVT cardiac disorders, was evaluated. First, we incorporated the biophysical modifications that are induced by the Na~v1.5~-p.R222Q and Na~v1.5~-p.I141V mutations and got insight on their effects on atrial, ventricular, and Purkinje APs using MGTG, TNNP, and SANNBZ models (Figures [5](#fig5){ref-type="fig"}, [6](#fig6){ref-type="fig"}, and [7](#fig7){ref-type="fig"}).

Interestingly, the introduction of equations mimicking the heterozygous state into the atrial and ventricular cell models induced minor changes in their AP morphologies (Figures [8(a)](#fig8){ref-type="fig"}, [8(b)](#fig8){ref-type="fig"}, [9(a)](#fig9){ref-type="fig"}, [9(b)](#fig9){ref-type="fig"}, [10(a)](#fig10){ref-type="fig"}, [10(b)](#fig10){ref-type="fig"}, [11(a)](#fig11){ref-type="fig"}, and [11(b)](#fig11){ref-type="fig"}). Conversely, Mann et al. and Swan et al. \[[@B3], [@B4]\] reported a drastic effect when these equations are introduced in the Purkinje cell model. Indeed, for the Na~v1.5~-p.R222Q and Na~v1.5~-p.I141V mutants, the model showed an accelerated rate of spontaneous activity of Purkinje cells leading to the occurrence of ectopic beats during the diastolic interval at 1 Hz (Figures [12(a)](#fig12){ref-type="fig"}, [12(b)](#fig12){ref-type="fig"}, [13(a)](#fig13){ref-type="fig"}, and [13(b)](#fig13){ref-type="fig"}). These abnormalities disappeared at higher pacing rates (Data not shown).

On the other hand, using MGTG, TNNP, and SANNBZ models, strength-duration curves were constructed. In the presence of Na~v1.5~-p.R222Q and Na~v1.5~-p.I141V mutations, a lower excitation threshold for action potential generation (pacing rates: 1 Hz for atrial and ventricular models and 2.5 Hz for the Purkinje model) was observed in the p.R222Q and p.I141V mutations in homozygous and heterozygous genotypes compared with the WT ((d) in Figures [8](#fig8){ref-type="fig"} [](#fig9){ref-type="fig"} [](#fig10){ref-type="fig"} [](#fig11){ref-type="fig"} [](#fig12){ref-type="fig"}--[13](#fig13){ref-type="fig"}).

Conduction velocity was investigated in fibers of MGTG, TNNP, and SANNBZ cell models (pacing rates, as described above). The presence of the Na~v1.5~-p.I141V mutation, in homozygous and heterozygous states, accelerated atrial and ventricular conduction at 1 Hz and Purkinje conduction at 2.5 Hz. Similar variations were observed in Na~v1.5~-p.R222Q mutation, whereas the conduction velocity was lower than WT condition in Purkinje cell model at 2.5 Hz pacing rate ([Table 4](#tab4){ref-type="table"}).

Of note, strength-duration curves and conduction velocities could not be established at 1 Hz in the Purkinje model because of the accelerated spontaneous rhythm caused by p.R222Q and p.I141V mutations.

3.3. Antiarrhythmic Effect of E3G on SCN5A-Related Cardiac Syndrome, MEPPC, and EPVT {#sec3.3}
------------------------------------------------------------------------------------

To investigate the potential antiarrhythmic effect of E3G on Na~v1.5~-p.R222Q and Na~v1.5~-p.I141V-related cardiac syndromes, the reported experimental effects of E3G were tested on these mutants. As shown in (a), (b), and (c) in Figures [8](#fig8){ref-type="fig"} [](#fig9){ref-type="fig"} [](#fig10){ref-type="fig"}--[11](#fig11){ref-type="fig"}, 30 *μ*M E3G does not affect the shape of action potentials in atrial and ventricular cells compared to the WT, Na~v1.5~-p.R222Q, and Na~v1.5~-p.I141V heterozygous conditions. However, this compound suppressed the ectopic APs observed in the presence of Na~v1.5~-p.R222Q mutation in Purkinje cell model ([Figure 12(c)](#fig12){ref-type="fig"}). Similar effects were obtained for Na~v1.5~-p.I141V mutation. Indeed, E3G decreased the number of ectopic beats associated with the presence of this mutation in Purkinje cells ([Figure 13(c)](#fig13){ref-type="fig"}). Of note, for these simulations, the models were stabilized during 60 s, then supplementary run was started for another 60 s, and finally the last 5 s of each supplementary run was analyzed.

Moreover, simulations were run using MGTG, TNNP, and SANNBZ cell models, and the strength-duration curves were constructed. In these models, the addition of 30 *μ*M E3G decreased the excitability of the atrial, ventricular, and Purkinje cells by increasing the excitation threshold for action potential generation ((e) and (f) in Figures [8](#fig8){ref-type="fig"} [](#fig9){ref-type="fig"} [](#fig10){ref-type="fig"} [](#fig11){ref-type="fig"} [](#fig12){ref-type="fig"}--[13](#fig13){ref-type="fig"}).

Finally, the effect of E3G on conduction velocity was investigated in the presence of p.R222Q and p.I141V mutations using fibers of atrial, ventricular, and Purkinje cell models. The presence of 30 *μ*M E3G attenuates the effect of p.R222Q and p.I141V mutations by decreasing atrial, ventricular, and Purkinje conductions. Of note, the conduction velocity was calculated at 1 Hz for the atrial and ventricular models and at 2.5 Hz for the Purkinje cells ([Table 4](#tab4){ref-type="table"}).

4. Discussion {#sec4}
=============

The aim of this study was to evaluate the benefits-risks balance of E3G consumption on the setting of cardiac channelopathies. Two gain-of-function mutations, Na~v1.5~-p.R222Q and Na~v1.5~-p.I141V, linked, respectively, with MEPPC and EPVT have been studied. Computer simulations of action potentials showed that 30 *μ*M E3G reduced the excitability of Purkinje cells for the EPVT and suppressed the AP abnormalities characteristic of the MEPPC phenotype.

4.1. Simulated Effect of E3G on the Electrophysiological Properties of Cardiac Cells {#sec4.1}
------------------------------------------------------------------------------------

Epigallocatechin-3-Gallate is the major catechin found in green tea. Tested at a dose of 30 *μ*M, E3G modulates several voltage gated ion channels such as sodium, L-type calcium, and KCNQ1 channels \[[@B8]\]. Thus, the perfusion of this catechin induces several electrocardiographic modifications in Langendorff-perfused guinea pig hearts \[[@B8]\]. Indeed, E3G prolonged PR and QRS intervals, slightly shortened the QT interval, and altered the shape of the ST-T-wave segment \[[@B8]\]. To explain the link between these effects,*in silico* E3G effects were reproduced as described by Kang et al. \[[@B8]\]. Then, the effect of these modifications was evaluated on cardiac action potentials. Either for atrial, ventricular, or Purkinje cell models, our simulations showed delayed action potentials upstrokes, decreased APs amplitudes, and reduced conduction velocity in these cell models. These effects are likely related to the inhibition of the cardiac sodium channel by E3G. In fact, these parameters result mainly from the passage of sodium ions through these channels. Therefore, E3G effects are reflected on the whole heart activity by the prolongation of the PR and QRS intervals.

On the other hand, the experimental work of Kang et al. showed a slight decrease of the QT interval when E3G is perfused \[[@B8]\]. These findings are consistent with our results showing a slight diminution of ventricular AP duration in presence of E3G. However, our simulations failed to explain the increase of the interval from the peak of the T wave to the end of the T wave (T~p~-T~e~) on the resting guinea pig ECG. This interval reflects the transmural dispersion of repolarization in the ventricle \[[@B20], [@B21]\]. Accordingly, it was shown that the increase of this interval could be associated with an increase of the repolarization heterogeneity across the ventricular wall with an increased risk of sudden cardiac death \[[@B22]\]. In contrast to these evidences, our results predicted a slight decrease of this heterogeneity.

4.2. The p.R222Q and p.I141V Effects on Cardiac Excitability {#sec4.2}
------------------------------------------------------------

In order to evaluate the possible antiarrhythmic effect of E3G in the sitting of MEPPC and EPVT cardiac disorders, the biophysical modifications induced by the Na~v1.5~-p.R222Q and Na~v1.5~-p.I141V mutants were incorporated as previously described by Mann et al. and Swan et al. \[[@B3], [@B4]\]. As shown by these groups, the introduction of these modifications into the atrial and ventricular cell models does not affect their AP morphologies. In contrast, the incorporation of the Na~v1.5~-p.R222Q and Na~v1.5~-p.I141V biophysical effects in the Purkinje cell model strongly affects the normal activation of these cells. Indeed, for these mutants, the model showed an accelerated rate of spontaneous activity of Purkinje cells leading to the occurrence of ectopic beats during the diastolic interval. In relevance to the disappearance of clinically observed premature contractions during exercise, the Purkinje ectopic APs induced by Na~v1.5~-p.R222Q mutation disappear at high pacing rates (Data not shown).

On the other hand, in atrial, ventricular, and Purkinje models, the presence of Na~v1.5~-p.R222Q and Na~v1.5~-p.I141V mutations lowers the excitation thresholds for action potential generation compared with the WT. Thus, threshold potential could be rapidly reached during the diastolic depolarization phase and consequently fire more action potentials in the Purkinje fiber compared to the WT condition. In contrast, atrial and ventricular cells do not show any spontaneous or ectopic activity in the presence of Na~v1.5~-p.R222Q and Na~v1.5~-p.I141V mutations. The biophysical modification induced by these mutations may promote the onset of arrhythmias by increasing the excitability of atrial and ventricular cells but cannot induce a spontaneous activation of these cells. Thus, as described by Laurent et al., the premature ventricular contraction observed in the affected patients may be triggered via the abnormal activity of the Purkinje fibers in the presence of p.R222Q and p.I141V mutations \[[@B2]\].

Moreover, the investigation of conduction velocity in fibers of MGTG, TNNP, and SANNBZ cell models shows an accelerated atrial, ventricular, and Purkinje conduction in the presence of Na~v1.5~-p.I141V mutation. Similar variations were observed in Na~v1.5~-p.R222Q mutation, whereas the conduction velocity was lower than WT condition in Purkinje cell model. The difference between the two mutations is related to the left shift of the steady state of inactivation shown by the Na~v1.5~-p.R222Q mutant. Indeed, when the Na~v1.5~-p.R222Q effect on the steady state of inactivation was suppressed, an increase of the conduction velocity was observed (Data not shown).

4.3. Antiarrhythmic Effect of E3G on the MEPPC and EPVT Syndromes {#sec4.3}
-----------------------------------------------------------------

By implementing the experimental functional effects of E3G on the cardiac ion channels, we investigated whether E3G had an antiarrhythmic effect on Na~v1.5~-p.R222Q and Na~v1.5~-p.I141V-related cardiac syndromes.

Regarding the Na~v1.5~-p.R222Q mutation, the application of 30 *μ*M E3G suppressed the ectopic APs characteristic of the MEPPC phenotype. However, at the same dose, E3G partially reduced the frequency of ectopic beats observed in Purkinje cells for the EPVT. These effects could be related to the inhibitory action of this compound on cardiac sodium channels, as was described in some antiarrhythmic drugs such as Quinidine and flecainide \[[@B2], [@B23]\]. In addition, the increase of excitation threshold for action potential generation and the decrease of conduction velocities, in the presence of 30 *μ*M E3G, may also limit the cardiac cells hyperexcitability that is related to gain of functions mutations of the cardiac sodium channels.

On the other hand, a clear difference in E3G effect was observed between the MEPPC and EPVT disorders. This difference could be explained by the biophysical properties of Na~v1.5~-p.R222Q and Na~v1.5~-p.I141V mutants. Indeed, in contrast to the Na~v1.5~-p.I141V mutation, known by the sole modification of the activation process of Na~v1.5~, the Na~v1.5~-p.R222Q mutation shifted the activation and inactivation processes towards more negative potentials \[[@B2], [@B3]\]. Therefore, E3G generated a more pronounced loss of function in the Na~v1.5~-p.R222Q mutant than the Na~v1.5~-p.I141V one. This is presumably due to the magnification of the negative shifts of Na~v1.5~ steady state inactivation induced in presence of both E3G and Na~v1.5~-p.R222Q.

5. Conclusion {#sec5}
=============

The present simulations suggest that E3G consumption may have a beneficial effect in the setting of cardiac sodium channelopathies displaying hyperexcitability phenotypes. Thus, this compound may offer a new promising alternative to prevent and treat the episodes of arrhythmia.
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=================

*Limitations of the Study*. The current study has several limitations: (i) the used cellular models did not incorporate the effects of adrenergic stimulation. (ii) Any biological variability was incorporated in these simulations. (iii) We assumed that WT and mutants ions channels have similar affinity to E3G. (iv) Kinetic effects of E3G were not considered in this study. (v) Cell-level arrhythmias such as early after depolarization and delayed after depolarization, or reentry, are not investigated in the current study. (vi) Any comparison of E3G effects was realized in the used action potential models.
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![Simulated effects of 30 *μ*M E3G in the human atrial model (MGTG (Maleckar-Greenstein-Trayanova-Giles)). (a) Steady state inactivation curves (*h* ~∞~) in the presence or absence of E3G. (b) and (c) Inhibitory effect of E3G on the sodium current at −90 mV and −70 mV resting potentials. (d) Inhibitory effect of E3G on the calcium current (20% inhibition). (e) Inhibitory effect of E3G on the *I* ~Ks~ current (50% inhibition). (f) E3G effect on the atrial action potential (intensity of stimulus = 15 *μ*A/*μ*F, duration: 6 ms; inset, zoom of the rapid depolarization phase). For all panels, black lines: without E3G; red lines: 30 *μ*M E3G.](CMMM2016-7861653.001){#fig1}

![Simulated effects of 30 *μ*M E3G in the human ventricular model (TNNP \[Tusscher--Noble--Noble--Panfilov\]). (a) Steady state inactivation curves (*h* ~∞~) in the presence or absence of E3G. (b) and (c) Inhibitory effect of E3G on the sodium current at −90 mV and −70 mV resting potentials. (d) Inhibitory effect of E3G on the calcium current (20% inhibition). (e) Inhibitory effect of E3G on the *I* ~Ks~ current (50% inhibition). (f) E3G effect on the midmyocardial action potential (intensity of stimulus = 52 *μ*A/*μ*F, duration: 1 ms; inset, zoom of the rapid depolarization phase). For all panels, black lines: without E3G; red lines: 30 *μ*M E3G.](CMMM2016-7861653.002){#fig2}

![Simulated effects of 30 *μ*M E3G in the human Purkinje model (SANNBZ (Stewart--Aslanidi--Noble--Noble--Boyett--Zhang Purkinje cell model)). (a) Steady state inactivation curves (*h* ~∞~) in the presence or absence of E3G. (b) and (c) Inhibitory effect of E3G on the sodium current at −90 mV and −70 mV resting potentials. (d) Inhibitory effect of E3G on the calcium current (20% inhibition). (e) Inhibitory effect of E3G on the *I* ~Ks~ current (25% inhibition: dashed line; 50% inhibition: solid line). (f) E3G effect on the Purkinje action potential (intensity of stimulus = 52 *μ*A/*μ*F, duration: 1 ms; inset, zoom of the rapid depolarization phase). For all panels, black lines: without E3G; red lines: 30 *μ*M E3G.](CMMM2016-7861653.003){#fig3}

![Repolarization dispersion across the ventricular wall. (a) Superimposition of the epi-, midmyo-, and endocardial action potentials (TNNP cells models) in absence of E3G. (b) Superimposition of the epi-, midmyo-, and endocardial action potentials in the presence of 30 *μ*M E3G.](CMMM2016-7861653.004){#fig4}

![Effects of the p.R222Q and p.I141V mutations on *I* ~Na~ properties in the human atrial cell model (MGTG cell model). (a) and (b) Effect of the p.R222Q mutation on the voltage dependence of steady state of activation and inactivation. (c) and (d) Effect of the p.R222Q mutation on the activation and inactivation kinetics. (e) and (f) Effect of the p.I141V mutation on the voltage dependence of steady state of activation and inactivation. (g) and (h) Effect of the p.I141V mutation on the activation and inactivation kinetics. For all panels, black lines: WT condition; red lines: mutant conditions.](CMMM2016-7861653.005){#fig5}

![Effects of the p.R222Q and p.I141V mutations on *I* ~Na~ properties in the human ventricular cell model (TNNP cell model). (a) and (b) Effect of the p.R222Q mutation on the voltage dependence of steady state of activation and inactivation. (c) and (d) Effect of the p.R222Q mutation on the activation and inactivation kinetics. (e) and (f) Effect of the p.I141V mutation on the voltage dependence of steady state of activation and inactivation. (g) and (h) Effect of the p.I141V mutation on the activation and inactivation kinetics. For all panels, black lines: WT condition; red lines: mutant conditions.](CMMM2016-7861653.006){#fig6}

![Effects of p.R222Q and p.I141V mutations on *I* ~Na~ properties in the human Purkinje cell model (SANNBZ cell model). (a) and (b) Effect of the p.R222Q mutation on the voltage dependence of steady state of activation and inactivation. (c) and (d) Effect of the p.R222Q mutation on the activation and inactivation kinetics. (e) and (f) Effect of the p.I141V mutation on the voltage dependence of steady state of activation and inactivation. (g) and (h) Effect of the p.I141V mutation on the activation and inactivation kinetics. For all panels, black lines: WT condition; red lines: mutant conditions.](CMMM2016-7861653.007){#fig7}

![Effects of 30 *μ*M E3G on atrial cell action potentials for Na~v1.5~-WT and Na~v1.5~-p.R222Q conditions (MGTG cell model). (a), (b), and (c) Simulated APs (Top of the panels) and the cardiac sodium currents (Bottom of the panels) in WT, heterozygous Na~v1.5~-p.R222Q, and heterozygous Na~v1.5~-p.R222Q + 30 *μ*M conditions at 1 Hz cycle length. Arrows: external stimulus. (d) and (e) Strength-duration curves in the MGTG cell model for Na~v1.5~-WT and heterozygous Na~v1.5~-p.R222Q conditions with or without 30 *μ*M E3G (inset, zoom on the strength-duration curves). (f) Excitation thresholds at 2 ms stimulus duration in the MGTG atrial AP or without 30 *μ*M E3G.](CMMM2016-7861653.008){#fig8}

![Effects of 30 *μ*M E3G on atrial cell action potentials for Na~v1.5~-WT and Na~v1.5~-p.I141V conditions (MGTG cell model). (a), (b), and (c) Simulated APs (Top of the panels) and the cardiac sodium currents (Bottom of the panels) in WT, heterozygous Na~v1.5~-p.I141V, and heterozygous Na~v1.5~-p.I141V + 30 *μ*M conditions at 1 Hz cycle length. Arrows: external stimulus. (d) and (e) Strength-duration curves in the MGTG cell model for Na~v1.5~-WT and heterozygous Na~v1.5~-p.I141V conditions with or without 30 *μ*M E3G (inset, zoom on the strength-duration curves). (f) Excitation thresholds at 2 ms stimulus duration in the MGTG atrial AP or without 30 *μ*M E3G.](CMMM2016-7861653.009){#fig9}

![Effects of 30 *μ*M E3G on ventricular cell action potentials for Na~v1.5~-WT and Na~v1.5~-p.R222Q conditions (TNNP cell model). (a), (b), and (c) Simulated APs (Top of the panels) and the cardiac sodium currents (Bottom of the panels) in WT, heterozygous Na~v1.5~-p.R222Q, and heterozygous Na~v1.5~-p.R222Q + 30 *μ*M conditions at 1 Hz cycle length. Arrows: external stimulus. (d) and (e) Strength-duration curves in the TNNP cell model for Na~v1.5~-WT and heterozygous Na~v1.5~-p.R222Q conditions with or without 30 *μ*M E3G (inset, zoom on the strength-duration curves). (f) Excitation thresholds at 2 ms stimulus duration in the TNNP atrial AP or without 30 *μ*M E3G.](CMMM2016-7861653.010){#fig10}

![Effects of 30 *μ*M E3G on ventricular cell action potentials for Na~v1.5~-WT and Na~v1.5~-p.I141V conditions (TNNP cell model). (a), (b), and (c) Simulated APs (Top of the panels) and the cardiac sodium currents (Bottom of the panels) in WT, heterozygous Na~v1.5~-p.I141V, and heterozygous Na~v1.5~-p.I141V + 30 *μ*M conditions at 1 Hz cycle length. Arrows: external stimulus. (d) and (e) Strength-duration curves in the TNNP cell model for Na~v1.5~-WT and heterozygous Na~v1.5~-p.I141V conditions with or without 30 *μ*M E3G (inset, zoom on the strength-duration curves). (f) Excitation thresholds at 2 ms stimulus duration in the TNNP atrial AP or without 30 *μ*M E3G.](CMMM2016-7861653.011){#fig11}

![Effects of 30 *μ*M E3G on Purkinje cell action potentials for Na~v1.5~-WT and Na~v1.5~-p.R222Q conditions (SANNBZ cell model). (a), (b), and (c) Simulated APs (Top of the panels) and the cardiac sodium currents (Bottom of the panels) in WT, heterozygous Na~v1.5~- p.R222Q, and heterozygous Na~v1.5~-p.R222Q + 30 *μ*M conditions at 1 Hz cycle length. Arrows: external stimulus. (d) and (e) Strength-duration curves in the SANNBZ cell model for Na~v1.5~-WT and heterozygous Na~v1.5~-p.R222Q conditions with or without 30 *μ*M E3G at 2.5 Hz (inset, zoom on the strength-duration curves). (f) Excitation thresholds at 2 ms stimulus duration in the SANNBZ atrial AP or without 30 *μ*M E3G.](CMMM2016-7861653.012){#fig12}

![Effects of 30 *μ*M E3G on Purkinje cell action potentials for Na~v1.5~-WT and Na~v1.5~-p.I141V conditions (SANNBZ cell model). (a), (b), and (c) Simulated APs (Top of the panels) and the cardiac sodium currents (Bottom of the panels) in WT, heterozygous Na~v1.5~-p.I141V, and heterozygous Na~v1.5~-p.I141V + 30 *μ*M conditions at 1 Hz cycle length. Arrows: external stimulus. (d) and (e) Strength-duration curves in the SANNBZ cell model for Na~v1.5~-WT and heterozygous Na~v1.5~-p.I141V conditions with or without 30 *μ*M E3G at 2.5 Hz (inset, zoom on the strength-duration curves). (f) Excitation thresholds at 2 ms stimulus duration in the SANNBZ atrial AP or without 30 *μ*M E3G.](CMMM2016-7861653.013){#fig13}

###### 

Formulation of WT and mutated sodium channels (Na~v1.5~-p.R222Q and Na~v1.5~-p.I141V) in the presence or absence of 30 *µ*M of E3G. The bold font corresponds to mutations effect and the bold-italic font to E3G effects.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                               TNNP/SANNBZ models, p.R222Q.*I* ~Na~                               TNNP/SANNBZ models, p.I141V.*I* ~Na~                           TNNP/SANNBZ models, *I* ~CaL~   TNNP/SANNB models, *I* ~Ks~
  ---------------------------------------------------------------------------- ------------------------------------------------------------------ -------------------------------------------------------------- ------------------------------- -----------------------------
  WT                                                                           *m* ~*∞*~, WT (*V* ~m~) = *m* ~*∞*~, WT (*V* ~m~)\                 *m* ~*∞*~, WT (*V* ~m~) = *m* ~*∞*~, WT (*V* ~m~)\             100% of *I* ~CaL~               100% of *I* ~Ks~
                                                                               *α* ~*m*~, WT (*V* ~m~) = *α* ~*m*~, WT (*V* ~m~)\                 *α* ~*m*~, WT (*V* ~m~) = *α* ~*m*~, WT (*V* ~m~)\                                             
                                                                               *β* ~*m*~ WT (*V* ~m~) = *β* ~*m*~, WT (*V* ~m~)\                  *β* ~*m*~ WT (*V* ~m~) = *β* ~*m*~, WT (*V* ~m~)\                                              
                                                                               *h* ~*∞*~, WT (*V* ~m~) = *h* ~*∞*~, WT (*V* ~m~)\                 *h* ~*∞*~, WT (*V* ~m~) = *h* ~*∞*~, WT (*V* ~m~)\                                             
                                                                               *β* ~*h*~WT (*V* ~m~) = *β* ~*m*~, WT (*V* ~m~)                    *β* ~*h*~ WT (*V* ~m~) = *β* ~*m*~, WT (*V* ~m~)                                               

                                                                                                                                                                                                                                                 

  WT + 30 *µ*M E3G                                                             *m* ~*∞*~, WT (*V* ~m~) = *m* ~*∞*~, WT (*V* ~m~)\                 *m* ~*∞*~, WT (*V* ~m~) = *m* ~*∞*~, WT (*V* ~m~)\             ***80%*** of *I* ~CaL~          ***50%*** of *I* ~Ks~
                                                                               *α* ~*m*~, WT (*V* ~m~) = *α* ~*m*~, WT (*V* ~m~)\                 *α* ~*m*~, WT (*V* ~m~) = *α* ~*m*~, WT (*V* ~m~)\                                             
                                                                               *β* ~*m*~ WT (*V* ~m~) = *β* ~*m*~, WT (*V* ~m~)\                  *β* ~*m*~ WT (*V* ~m~) = *β* ~*m*~, WT (*V* ~m~)\                                              
                                                                               *h* ~*∞*~, WT (*V* ~m~) = *h* ~*∞*~, WT (*V* ~m~ + ***6***)\       *h* ~*∞*~, WT (*V* ~m~) = *h* ~*∞*~, WT (*V* ~m~ + ***6***)\                                   
                                                                               *β* ~*h*~WT (*V* ~m~) = *β* ~*h*~, WT (*V* ~m~)                    *β* ~*h*~WT (*V* ~m~) = *β* ~*h*~, WT (*V* ~m~)                                                

                                                                                                                                                                                                                                                 

  Mutants                                                                      *m* ~*∞*~, p.I141V (*V* ~m~) = *m* ~*∞*~, WT (*V* ~m~ − 6.3)       *m* ~*∞*~, p.I141V (*V* ~m~) = *m* ~*∞*~, WT (*V* ~m~ − 7)     100% of *I* ~CaL~               100% of *I* ~Ks~

  *α* ~*m*~, p.I141V (*V* ~m~) = *α* ~*h*~, WT (*V* ~m~)                       *α* ~*m*~, p.I141V (*V* ~m~) = *α* ~*h*~, WT (*V* ~m~ − 7)                                                                                                        

  *β* ~*m*~, p.I141V (*V* ~m~) = *β* ~*h*~, WT (*V* ~m~)                       *β* ~*m*~, p.I141V (*V* ~m~) = *β* ~*h*~, WT (*V* ~m~ + **7**)                                                                                                    

  *h* ~*∞*~, p.I141V (*V* ~m~) = *h* ~*∞*~, WT (*V* ~m~ + **6.2**)\            *h* ~*∞*~, p.I141V (*V* ~m~) = *h* ~*∞*~, WT (*V* ~m~)\                                                                                                           
  *β* ~*h*~WT (*V* ~m~) = *β* ~*h*~, WT (*V* ~m~)                              *β* ~*h*~WT (*V* ~m~) = *β* ~*h*~, WT (*V* ~m~ + **7**)                                                                                                           

                                                                                                                                                                                                                                                 

  Mutants + 30 *µ*M E3G                                                        *m* ~*∞*~, p.I141V (*V* ~m~) = *m* ~*∞*~, WT (*V* ~m~ − 6.3)       *m* ~*∞*~, p.I141V (*V* ~m~) = *m* ~*∞*~, WT (*V* ~m~ − 7)     ***80%*** of *I* ~CaL~          ***50%*** of *I* ~Ks~

  *α* ~*m*~, p.I141V (*V* ~m~) = *α* ~*h*~, WT (*V* ~m~)                       *α* ~*m*~, p.I141V (*V* ~m~) = *α* ~*h*~, WT (*V* ~m~ − 7)                                                                                                        

  *β* ~*m*~, p.I141V (*V* ~m~) = *β* ~*h*~, WT (*V* ~m~)                       *β* ~*m*~, p.I141V (*V* ~m~) = *β* ~*h*~, WT (*V* ~m~ + **7**)                                                                                                    

  *h* ~*∞*~, p.I141V (*V* ~m~) = *h* ~*∞*~, WT (*V* ~m~ + **6.2** + ***6***)   *h* ~*∞*~, p.I141V (*V* ~m~) = *h* ~*∞*~, WT (*V* ~m~ + ***6***)                                                                                                  

  *β* ~*h*~WT (*V* ~m~) = *β* ~*h*~, WT (*V* ~m~)                              *β* ~*h*~WT (*V* ~m~) = *β* ~*h*~, WT (*V* ~m~ + **7**)                                                                                                           
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Formulation of WT and mutated sodium channels (Na~v1.5~-p.R222Q and Na~v1.5~-p.I141V) in the presence or absence of 30 *µ*M of E3G in the Maleckar-Greenstein-Trayanova-Giles atrial cell model. The bold font corresponds to mutations effect and the bold-italic font to E3G effects.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                    MGTG atrial model, p.R222Q.*I* ~Na~                                               MGTG atrial model, p.I141V.*I* ~Na~                          MGTG atrial model, *I* ~CaL~    MGTG atrial model, *I* ~Ks~
  --------------------------------------------------------------------------------- --------------------------------------------------------------------------------- ----------------------------------------------------------- ------------------------------- ------------------------------
  * *WT                                                                             *m* ~*∞*~, WT (*V* ~m~) = *m* ~*∞*~, WT (*V* ~m~)                                 *m* ~*∞*~, WT (*V* ~m~) = *m* ~*∞*~, WT (*V* ~m~)           100% of *I* ~CaL~               100% of *I* ~Ks~

  *m* factor, WT (*V* ~m~) = *m* factor, WT (*V* ~m~)\                              *m* factor, WT (*V* ~m~) = *m* factor, WT (*V* ~m~)\                                                                                                                          
  *τ* ~*m*~ = 4.2*e* − 5 (s)*∗*exp⁡(−*m* ~factor~ *∗m* ~factor~) + 2.4*e* − 5 (s)   *τ* ~*m*~ = 4.2*e* − 5 (s)*∗*exp⁡(−*m* ~factor~ *∗m* ~factor~) + 2.4*e* − 5 (s)                                                                                               

  *h* ~*∞*~, WT (*V* ~m~) = *h* ~*∞*~, WT (*V* ~m~)                                 *h* ~*∞*~, WT (*V* ~m~) = *h* ~*∞*~, WT (*V* ~m~)                                                                                                                             

  *h* factor, WT (*V* ~m~) = *h* factor, WT (*V* ~m~)                               *h* factor, WT (*V* ~m~) = *h* factor, WT (*V* ~m~)                                                                                                                           

                                                                                    *τ* ~*h*1~ = 0.03 (s) *∗h* ~factor~ + 0.0003 (s)                                  *τ* ~*h*1~ = 0.03 (s) *∗*   *h* ~factor~ + 0.0003 (s)                                       

                                                                                                                                                                                                                                                                  

  WT + 30 *µ*M E3G                                                                  *m* ~*∞*~, WT (*V* ~m~) = *m* ~*∞*~, WT (*V* ~m~)                                 *m* ~*∞*~, WT (*V* ~m~) = *m* ~*∞*~, WT (*V* ~m~)           ***80%*** of *I* ~CaL~          ***50%*** of *I* ~Ks~

  *m* factor, WT (*V* ~m~) = *m* factor,\                                           *m* factor, WT (*V* ~m~) = *m* factor, WT (*V* ~m~)                                                                                                                           
  WT (*V* ~m~)                                                                                                                                                                                                                                                    

  *τ* ~*m*~ = 4.2*e* − 5 (s)*∗*exp⁡(−*m* ~factor~ *∗m* ~factor~) + 2.4*e* − 5 (s)   *τ* ~*m*~ = 4.2*e* − 5 (s)*∗*exp⁡(−*m* ~factor~ *∗m* ~factor~) + 2.4*e* − 5 (s)                                                                                               

  *h* ~*∞*~, WT (*V* ~m~) = *h* ~*∞*~, WT (*V* ~m~ + ***6***)                       *h* ~*∞*~, WT (*V* ~m~) = *h* ~*∞*~, WT (*V* ~m~ + ***6***)                                                                                                                   

  *h* factor, WT (*V* ~m~) = *h* factor, WT (*V* ~m~)                               *h* factor, WT (*V* ~m~) = *h* factor, WT (*V* ~m~)                                                                                                                           

  *τ* ~*h*1~ = 0.03 (s) *∗*   *h* ~factor~ + 0.0003 (s)                             *τ* ~*h*1~ = 0.03 (s) *∗*   *h* ~factor~ + 0.0003 (s)                                                                                                                         

                                                                                                                                                                                                                                                                  

  Mutants                                                                           *m* ~*∞*~, WT (*V* ~m~) = *m* ~∞~, WT (*V* ~m~ + **6.3**)                         *m* ~*∞*~, WT (*V* ~m~) = *m* ~*∞*~, WT (*V* ~m~ + **7**)   100% of *I* ~CaL~               100% of *I* ~Ks~

  *m* factor, WT (*V* ~m~) = *m* factor, WT (*V* ~m~)                               *m* factor, WT (*V* ~m~) = *m* factor, WT (*V* ~m~ + **7**)                                                                                                                   

  *τ* ~*m*~ = 4.2*e* − 5 (s)*∗*exp⁡(−*m* ~factor~ *∗m* ~factor~) + 2.4*e* − 5 (s)   *τ* ~*m*~ = 4.2*e* − 5 (s)*∗*exp⁡(−*m* ~factor~ *∗m* ~factor~) + 2.4*e* − 5 (s)                                                                                               

  *h* ~*∞*~, WT (*V* ~m~) = *h* ~*∞*~, WT (*V* ~m~ + **6.2**)                       *h* ~*∞*~, WT (*V* ~m~) = *h* ~*∞*~, WT (*V* ~m~)                                                                                                                             

  *h* factor, WT (*V* ~m~) = *h* factor, WT (*V* ~m~)                               *h* factor, WT (*V* ~m~) = *h* factor, WT (*V* ~m~ + **7**)                                                                                                                   

  *τ* ~*h*1~ = 0.03 (s) *∗*   *h* ~factor~ + 0.0003 (s)                             *τ* ~*h*1~ = 0.03 (s) *∗*   *h* ~factor~ + 0.0003 (s)                                                                                                                         

                                                                                                                                                                                                                                                                  

  Mutants + 30 *µ*M E3G                                                             *m* ~*∞*~, WT (*V* ~m~) = *m* ~*∞*~, WT (*V* ~m~ + **6.3**)                       *m* ~*∞*~, WT (*V* ~m~) = *m* ~*∞*~, WT (*V* ~m~ + **7**)   ***80%*** of *I* ~CaL~          ***50%*** of *I* ~Ks~

  *m* factor, WT (*V* ~m~) = *m* factor, WT (*V* ~m~)                               *m* factor, WT (*V* ~m~) = *m* factor, WT (*V* ~m~ + **7**)                                                                                                                   

  *τ* ~*m*~ = 4.2*e* − 5 (s)*∗*exp⁡(−*m* ~factor~ *∗m* ~factor~) + 2.4*e* − 5 (s)   *τ* ~*m*~ = 4.2*e* − 5 (s)*∗*exp⁡(−*m* ~factor~ *∗m* ~factor~) + 2.4*e* − 5 (s)                                                                                               

  *h* ~*∞*~, WT (*V* ~m~) = *h* ~*∞*~, WT (*V* ~m~ + **6.2** + ***6***)             *h* ~*∞*~, WT (*V* ~m~) = *h* ~*∞*~, WT (*V* ~m~ + ***6***)                                                                                                                   

  *h* factor, WT (*V* ~m~) = *h* factor, WT (*V* ~m~)                               *h* factor, WT (*V* ~m~) = *h* factor, WT (*V* ~m~ + **7**)                                                                                                                   

  *τ* ~*h*1~ = 0.03 (s) *∗*   *h* ~factor~ + 0.0003 (s)                             *τ* ~*h*1~ = 0.03 (s) *∗*   *h* ~factor~ + 0.0003 (s)                                                                                                                         
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

A summary of the parameters used for the calculation of conduction velocity in the atrial, ventricular, and Purkinje models.

  -----------------------------------------------------------------
  Model    Cell number\   Intercellular conductance\   Step size\
           (*n*)          (mS/*µ*F)                    (ms)
  -------- -------------- ---------------------------- ------------
  MGTG     100            17                           0.01

  SANNBZ   100            17                           0.01

  TNNP     100            7                            0.001
  -----------------------------------------------------------------

###### 

The effect of E3G on conduction velocity investigations in the presence of p.R222Q and p.I141V in heterozygous states.

  Model              Atrial cells   Ventricular cells   Purkinje cells                   
  ------------------ -------------- ------------------- ---------------- ------- ------- ---------
  Na~v1.5~ WT        55.07          50.84               49.91            45.72   67.68   37.20
  Na~v1.5~ p.I141V   57.44          53.93               53.63            49.11   72.43   42\. 92
  Na~v1.5~ p.R222Q   60.93          56.23               51.93            45.56   62.72   ---
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